The first case of a rare blood clot has been recorded in Canada after a dose of the AstraZeneca-Oxford COVID-19 vaccine.
Quebec’s Ministry of Health and Social Services has confirmed someone in the province experienced an adverse event known as VIPIT. Ministry didn’t confirm gender or age of the patient but, Christian Dubé, Health Minister, later identified the individual as a woman.
The National Advisory Committee on Immunization (NACI) said that VIPIT occurs at a rate of on in 100 thousand vaccinated people. Its mortality rate is of 40 percent, but the risk is reduced if the condition is treated early enough.
Dubé said the province is taking a “hypervigilant” approach and monitoring any adverse reactions related to the vaccine. He said this was a possibility that health officials “expected” and prepared for. During a news conference on Tuesday, he said: “The good news is, the woman in question was taken care of and she’s doing well.”
A few weeks back, Europe placed a halt on their vaccination program also due to blood clots after the AstraZeneca jab.
Likewise, the Johnson & Johnson (J&J) vaccine has been temporarily suspended un the US, South Africa and the European Union due to reports of rare blood clotting. The US Food and Drug Administration (FDA) said that six cases were detected in 6.8 million doses of the jab.
All cases occurred in women between the ages of 18 and 48. Symptoms appeared six to 13 days after receiving the dose.